EL7.AI
StocksMediumUpdated•Originally published 23 September 2026•Updated 23 September 2026•
2 min read

Caliway’s CBL-514 Beats Placebo on Pain Reduction in Phase 2 Trial

Key Facts

1At Week 20, the mean pain score fell 3.1 points with CBL-514 versus 1.9 points with placebo, at p=0.005.
2At Weeks 16 and 24, pain fell 3.5 and 4.1 points with CBL-514 versus 1.7 points with placebo at both assessments.
3The company said about 90% of recipients achieved a reduction of at least 3 points in more than half of treated painful lipomas, with no drug-related serious adverse events reported.

Caliway Biopharmaceuticals said its randomized, single-blind, placebo-controlled CBL-0202DD Phase 2 trial of CBL-514 met its primary endpoint in patients with Dercum’s disease. At Week 20, the mean pain score in the Full Analysis Set fell 3.1 points with CBL-514, compared with 1.9 points for placebo, a statistically significant difference of p=0.005.

The difference persisted at the secondary assessment points, according to the company. Mean pain scores declined 3.5 points with CBL-514 at Week 16 and 4.1 points at Week 24, versus 1.7 points with placebo at both points; the respective significance levels were p=0.0017 and p<0.0001.

In an exploratory analysis, Caliway said about 90% of CBL-514 recipients achieved a pain reduction of at least 3 points in more than half of their treated painful lipomas. No drug-related serious adverse events were reported, while the most common events were mild-to-moderate local injection-site reactions. The company says the drug induces programmed death of fat cells, but it remains in clinical development and is not an approved treatment.

Caliway is listed on the Taiwan Stock Exchange under 6919.TW. For investors, the positive result reduces some clinical uncertainty around the program but does not amount to regulatory approval: converting the efficacy signal into potential revenue will require later-stage evidence and regulatory review.